help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murgo, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murgo, A. J.
The Oncologist, Vol. 6, Suppl 2, 22-28, April 2001
© 2001 AlphaMed Press

SUPPLEMENT

Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies

Anthony J. Murgo

Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA

Correspondence: Anthony J. Murgo, M.D., Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd., EPN Suite 7131, Rockville, Maryland, 20852-4910, USA. Telephone: 301-496-1196; Fax: 301-402-0428; e-mail: Murgoa{at}ctep.nci.nih.GOV

Arsenic trioxide inhibits growth and promotes apoptosis in many different cancer cell lines. The National Cancer Institute is working cooperatively with research centers across the U.S. to evaluate its clinical activity in hematologic malignancies, such as acute promyelocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. It is also supporting research in solid tumors, such as advanced hormone-refractory prostate cancer and renal cell cancer and in cervical cancer and refractory transitional cell carcinoma of the bladder. The safety and pharmacokinetics of arsenic trioxide are also being evaluated in pediatric patients with refractory leukemia and lymphoma. The results of these ongoing studies should provide important insights into the clinical utility of arsenic trioxide in these diseases.

Key Words. Arsenic trioxide • National Cancer Institute • Hematologic malignancy • Solid tumor




This article has been cited by other articles:


Home page
 IOVSHome page
J. H. Kim, J. H. Kim, Y. S. Yu, D. H. Kim, C. J. Kim, and K.-W. Kim
Antitumor Activity of Arsenic Trioxide on Retinoblastoma: Cell Differentiation and Apoptosis Depending on Arsenic Trioxide Concentration
Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1819 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. E. Rosenblatt and K. L. Burnstein
Inhibition of Androgen Receptor Transcriptional Activity as a Novel Mechanism of Action of Arsenic
Mol. Endocrinol., March 1, 2009; 23(3): 412 - 421.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
V. L. Bae-Jump, Chunxiao Zhou, J. F. Boggess, and P. A. Gehrig
Arsenic Trioxide (As2O3) Inhibits Expression of Estrogen Receptor--alpha Through Regulation of the Mitogen-activated Protein Kinase (MAPK) Pathway in Endometrial Cancer Cells
Reproductive Sciences, December 1, 2008; 15(10): 1011 - 1017.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Kumar, Q. Gao, Y. Ning, Z. Wang, P. H. Krebsbach, and P. J. Polverini
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
Mol. Cancer Ther., July 1, 2008; 7(7): 2060 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Peng, L. Peng, Y. Fan, E. Zandi, H. G. Shertzer, and Y. Xia
A Critical Role for I{kappa}B Kinase beta in Metallothionein-1 Expression and Protection against Arsenic Toxicity
J. Biol. Chem., July 20, 2007; 282(29): 21487 - 21496.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Chen, R. Chan, S. Waxman, and Y. Jing
Buthionine Sulfoximine Enhancement of Arsenic Trioxide-Induced Apoptosis in Leukemia and Lymphoma Cells Is Mediated via Activation of c-Jun NH2-Terminal Kinase and Up-regulation of Death Receptors
Cancer Res., December 1, 2006; 66(23): 11416 - 11423.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. F. Taylor, S. C. McNeely, H. L. Miller, G. M. Lehmann, M. J. McCabe Jr., and J. C. States
p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21CIP1/WAF1
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 142 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Karlsson, A. Edsjo, S. Pahlman, and H. M. Pettersson
Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia
Mol. Cancer Ther., July 1, 2005; 4(7): 1128 - 1135.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Karasavvas, J. M. Carcamo, G. Stratis, and D. W. Golde
Vitamin C protects HL60 and U266 cells from arsenic toxicity
Blood, May 15, 2005; 105(10): 4004 - 4012.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Z. Diaz, M. Colombo, K. K. Mann, H. Su, K. N. Smith, D. S. Bohle, H. M. Schipper, and W. H. Miller Jr
Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines
Blood, February 1, 2005; 105(3): 1237 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Hines-Peralta and S. N. Goldberg
Review of Radiofrequency Ablation for Renal Cell Carcinoma
Clin. Cancer Res., September 15, 2004; 10(18): 6328S - 6334S.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. D. Pegram, T. Pienkowski, D. W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, et al.
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
J Natl Cancer Inst, May 19, 2004; 96(10): 759 - 769.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Fernandez, A. M. Ramos, P. Sancho, D. Amran, E. de Blas, and P. Aller
12-O-Tetradecanoylphorbol-13-acetate May Both Potentiate and Decrease the Generation of Apoptosis by the Antileukemic Agent Arsenic Trioxide in Human Promonocytic Cells: REGULATION BY EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASES AND GLUTATHIONE
J. Biol. Chem., January 30, 2004; 279(5): 3877 - 3884.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
N. V. Soucy, M. A. Ihnat, C. D. Kamat, L. Hess, M. J. Post, L. R. Klei, C. Clark, and A. Barchowsky
Arsenic Stimulates Angiogenesis and Tumorigenesis In Vivo
Toxicol. Sci., December 1, 2003; 76(2): 271 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Nimmanapalli, P. Bali, E. O'Bryan, L. Fuino, F. Guo, J. Wu, P. Houghton, and K. Bhalla
Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells
Cancer Res., November 15, 2003; 63(22): 7950 - 7958.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. McCafferty-Grad, N. J. Bahlis, N. Krett, T. M. Aguilar, I. Reis, K. P. Lee, and L. H. Boise
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells
Mol. Cancer Ther., November 1, 2003; 2(11): 1155 - 1164.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
P. B. Tchounwou, A. K. Patlolla, and J. A. Centeno
Invited Reviews: Carcinogenic and Systemic Health Effects Associated with Arsenic Exposure--A Critical Review
Toxicol Pathol, October 1, 2003; 31(6): 575 - 588.
[Abstract] [PDF]

Home page
 BloodHome page
S. Mathas, A. Lietz, M. Janz, M. Hinz, F. Jundt, C. Scheidereit, K. Bommert, and B. Dorken
Inhibition of NF-{kappa}B essentially contributes to arsenic-induced apoptosis
Blood, August 1, 2003; 102(3): 1028 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. C. A. Duyndam, S. T. M. Hulscher, E. van der Wall, H. M. Pinedo, and E. Boven
Evidence for a Role of p38 Kinase in Hypoxia-inducible Factor 1-independent Induction of Vascular Endothelial Growth Factor Expression by Sodium Arsenite
J. Biol. Chem., February 21, 2003; 278(9): 6885 - 6895.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Vernhet, N. Allain, M. Le Vee, F. Morel, A. Guillouzo, and O. Fardel
Blockage of Multidrug Resistance-Associated Proteins Potentiates the Inhibitory Effects of Arsenic Trioxide on CYP1A1 Induction by Polycyclic Aromatic Hydrocarbons
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 145 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res., July 15, 2002; 62(14): 3893 - 3903.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. L. Slack, S. Waxman, G. Tricot, M. S. Tallman, and C. D. Bloomfield
Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide
Oncologist, April 1, 2002; 7(90001): 1 - 13.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. C. A. Duyndam, T. M. Hulscher, D. Fontijn, H. M. Pinedo, and E. Boven
Induction of Vascular Endothelial Growth Factor Expression and Hypoxia-inducible Factor 1alpha Protein by the Oxidative Stressor Arsenite
J. Biol. Chem., December 14, 2001; 276(51): 48066 - 48076.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Crown
Docetaxel: Overview of an Active Drug for Breast Cancer
Oncologist, June 1, 2001; 6(2008): 1 - 4.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.